Tumor mutation burden (TMB) and immune- related adverse events (irAEs) compared to antibiotic (abx) use to predict for response to immune checkpoint inhibitors in esophagogastric cancer (EGC) Meeting Abstract
| Authors: | Greally, M.; Chatila, W. K.; Margolis, M.; Hechtman, J. F.; Tuvy, Y.; Kundra, R.; Ladanyi, M.; Kelsen, D. P.; Ilson, D. H.; Berger, M. F.; Tang, L. H.; Solit, D. B.; Schultz, N.; Janjigian, Y. Y.; Ku, G. Y. |
| Abstract Title: | Tumor mutation burden (TMB) and immune- related adverse events (irAEs) compared to antibiotic (abx) use to predict for response to immune checkpoint inhibitors in esophagogastric cancer (EGC) |
| Meeting Title: | 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 36 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2018 Jun 1-5 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2018-05-20 |
| Start Page: | 215s |
| Language: | English |
| ACCESSION: | WOS:000442916001633 |
| DOI: | 10.1200/JCO.2018.36.15_suppl.4056 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 4056 -- Source: Wos |
